Heinz Wiendl
Has participated in:
-
Alemtuzumab : humanisierter monoklonaler Antikörper in der MS-Therapie
-
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders
-
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
-
Ofatumumab : neue Perspektiven für eine zielgerichtete Therapie der aktiven schubförmigen multiplen Sklerose